Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Phoenix & Scottsdale, AZ

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 11:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
608
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Phoenix & Scottsdale, AZ
Additional filters apply within this campus.

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

Filter and sort this campus

These controls apply only within Mayo Clinic, Phoenix & Scottsdale, AZ. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 481–492 of 608 matching trials with a site at Mayo Clinic, Phoenix & Scottsdale, AZ.
Indexed local directory records.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Stored official records

Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies

NCT06720987
Status at this site: Recruiting
View directory record Official record
Conditions
CRC (Colorectal Cancer), KRAS G12C Mutation, KRAS G12S Mutation, Solid Tumor Malignancies
Interventions
Cetuximab, KQB198, KQB365
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
11
States / cities
Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 14, 2026, 4:25 PM EDT
Recruiting Phase 3 Interventional

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

NCT04852887
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Stage I Breast Cancer
Interventions
Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Radiation and Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane)
Drug · Other
Lead sponsor
NRG Oncology
Other
Eligibility
50 Years to 70 Years
Enrollment
1,670 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2041
U.S. locations
812
States / cities
Birmingham, Alabama • Mobile, Alabama • Kingman, Arizona + 553 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 14, 2026, 12:54 AM EDT
Recruiting Phase 2 Interventional

Reduced Dose Radiotherapy for the Treatment of Indolent Non-Hodgkin Lymphoma

NCT06386315
Status at this site: Recruiting
View directory record Official record
Conditions
Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Refractory Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma
Interventions
Computed Tomography, Endoscopic Procedure, Involved-site Radiation Therapy (12 Fractions), Involved-site Radiation Therapy (3 Fractions), Positron Emission Tomography, Questionnaire Administration
Procedure · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Albert Lea, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 14, 2026, 10:59 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies

NCT04349436
Site status not listed — check the official record
View directory record Official record
Conditions
Basal Cell Carcinoma, Cancer, Locally Advanced Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma
Interventions
RP1, intra-tumoral injection, oncolytic virus
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
24
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 14, 2026, 12:58 PM EDT
Active, not recruiting No phase listed Observational

Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study

NCT06350734
Site status not listed — check the official record
View directory record Official record
Conditions
Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 9, 2026, 8:07 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI

NCT06315595
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Prostate Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2030
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 16, 2026, 2:38 AM EDT
Recruiting Early Phase 1 Interventional

Growth Hormone for the Treatment of Gastroparesis

NCT06803589
Status at this site: Recruiting
View directory record Official record
Conditions
Gastroparesis
Interventions
Growth Hormone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Phoenix, Arizona • Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Sep 17, 2026, 7:06 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)

NCT03157128
Site status not listed — check the official record
View directory record Official record
Conditions
Any Solid Tumor, Colon Cancer, Medullary Thyroid Cancer, Non-Small Cell Lung Cancer
Interventions
LOXO-292
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
41
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 20, 2026, 11:14 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

NCT05605899
Site status not listed — check the official record
View directory record Official record
Conditions
High-risk Large B-cell Lymphoma (LBCL)
Interventions
Axicabtagene Ciloleucel, Cyclophosphamide, Doxorubicin, Etoposide, Fludarabine, Prednisone, Rituximab, Vincristine
Biological · Drug
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
32
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 16, 2026, 12:47 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients

NCT07185880
Status at this site: Recruiting
View directory record Official record
Conditions
Glioblastoma (GBM)
Interventions
MT-125
Drug
Lead sponsor
Myosin Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 14, 2026, 4:07 AM EDT
Active, not recruiting Not applicable Interventional

A PIVOTAL STUDY EVALUATING SAFETY AND EFFICACY OF THE SHIRATRONICS MIGRAINE THERAPY SYSTEM

NCT06167655
Site status not listed — check the official record
View directory record Official record
Conditions
Headache Migraine Chronic
Interventions
Neurostimulator
Device
Lead sponsor
ShiraTronics
Industry
Eligibility
22 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
20
States / cities
Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Jul 27, 2026, 6:38 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

NCT05732103
Status at this site: Recruiting
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
CTX-712
Drug
Lead sponsor
Chordia Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
8
States / cities
Phoenix, Arizona • Jacksonville, Florida • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Jul 29, 2026, 5:35 AM EDT

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Phoenix & Scottsdale, AZ as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.